HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Gillette

This article was originally published in The Rose Sheet

Executive Summary

Gillette: Funding two $50,000 grants for the research and development of non-animal testing methods, the company said. The recipients of the grants are Dennis DeLuca, PhD, and Craig Elmets, MD, of the Department of Dermatology at the Case Western School of Medicine and James Zieske, PhD, of the Schepens Eye Research Institute. DeLuca and Elmets will investigate dermatitis "with the goal of producing an in vitro alternative to animals for skin irritancy testing," while Zieske will research methods of developing an in vitro eye irritancy model by culturing human cornea cells. Gillette has recently come under fire by animal rights groups; the People for the Ethical Treatment of Animals filed a complaint with the Federal Trade Commission in February claiming that Gillette engages in "false, misleading, and deceptive" advertising by stating among other things, that "it must use animal tests in order to comply with governmental requirements." ("The Rose Sheet" March 4, p. 8)
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel